Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis
Introduction: Metastasis to the central nervous system (CNS) is frequently observed in human epidermal growth factor receptor (HER2)-positive breast cancer, leading to reduced quality of life and poor prognosis. Brain metastases (BMs) are common, whereas spinal cord metastases are ra...
Saved in:
| Main Authors: | Hiroaki Yamane, Tomoko Itagaki, Keiko Kajitani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-12-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000542761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01) -
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01) -
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01) -
Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023-10-01) -
Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)